A subset of bone cancer patients may respond to IGF1R inhibitors based on their genetic profile A subgroup of patients with osteosarcoma — a form of bone cancer — could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer Institute and the...